Lower baseline eGFR and a history of coronary artery disease may predict the risk for hemodialysis after total artificial heart implantation.
Most programs put live-donor transplants on hold.
COVID-19was found to be associated with a higher fatality rate in recipients of heart transplant.
Heart transplant (HT) recipients with COVID-19 infection have a case fatality rate of 25 percent.
Heart transplant with or without bridge to transplant LVAD therapy was found to be associated with greater 5-year survival compared with LVAD destination therapy in patients with end-stage heart failure.
Investigations into the presentation and prognosis of the novel coronavirus disease 2019 in patients who have received a heart transplant are needed.
The Food and Drug Administration approved the 50cc temporary Total Artificial Heart System developed and manufactured by SynCardia Systems, LLC as a bridge to heart transplant for patients who are at imminent risk for death from biventricular failure.
Multisociety Lifelong Learning Statement focuses on learning competencies necessary for advanced heart failure and transplant cardiology specialists.
There is great variability in donor heart acceptance decisions among US transplant centers.
Patients who received heart transplants from hepatitis C virus-positive vs -negative donors were found to have comparable survival at 1 year and patients who developed transplant-related hepatitis C responded well to treatment.